

DAI-ICHI KARKARIA LTD.
REGD.OFFICE: LIBERTY BUILDING, SIR VITHALDAS THACKERSEY MARG,
MUMBAI 400 020.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS
ENDED 31st DECEMBER, 2005

PARTICULARS	Quarter ended 31-12-2005 Rs./lacs (Unaudited)	Quarter ended 31-12-2004 Rs./lacs Unaudited	Nine Months Ended 31-12-2005 Rs./lacs Unaudited	Nine Months Ended 31-12-2004 Rs./lacs (Unaudited)	Year ended 31-03-2005 Rs./lacs Audited
A. Operating result for the period					
1. Net Sales/Other Operating Income	995	1,368	3,807	3,572	4,664
2. Other Income	113	14	624	139	166
3. Total Expenditure	1,387	1,360	4,187	3,537	4,531
a) (Increase)/Decrease in stock in trade	142	23	150	(117)	(49)
b) Consumption of raw and packing materials	712	881	2,523	2,365	2,983
c) Staff Cost	147	178	505	509	674
d) Other expenditure	386	278	1,009	780	923
4. Interest	34	49	98	137	175
5. Depreciation	24	53	132	160	215
6. Profit/(Loss) before tax	(337)	(80)	14	(123)	(91)
7. Exceptional Item- Income/ (Expense) net	836	21	807	64	10
8 Profit/(Loss) After Exceptional Item	499	(101)	821	(187)	(101)
9. Provision for taxation					
a) Current Tax	420	0	443	0	2
b) Fringe Benefit Tax	2		7		
b) Deferred Tax	0	0	0	0	41
10. Profit/(Loss) after Tax	77	(101)	371	(187)	(144)
11. Add/(Less) : Prior Year's adjustment	0	0	0	0	0
12. Net Profit/(Loss)	77	(101)	371	(187)	(144)
13. Paid-up Equity Share Capital (Face value Rs.10/- per share)	761	761	761	761	761
14. Reserves excluding Revaluation Reserves.	0	0	0	0	3,286
15. Earning Per Share	1.01	(1.33)	4.88	(2.46)	(1.90)
16. Earning Per Share (excluding exceptional items)	(4.43)	(1.05)	0.18	(1.62)	(1.76)
17. Aggregate Non-Promoter Shareholding. No. of shares	3,078,890	2,954,002	3,078,890	2,954,002	2,954,002
Percentage of Shareholding	40.48%	38.84%	40.48%	38.84%	38.84%

SEGMENT - WISE REVENUE, RESULTS AND CAPITAL EMPLOYED	Quarter ended 31-12-2005 Rs./lacs (Unaudited)	Quarter ended 31-12-2004 Rs./lacs Unaudited	Three Months En 31-12-2005 Rs./lacs Unaudited	Three Months En 31-12-2004 Rs./lacs (Unaudited)	Year ended 31-03-2005 Rs./lacs Audited
1. SEGMENT REVENUE					

a) Speciality Chemicals	1,010	1,171	3,404	3,092	3,950
b) Drugs & Formulations	99	211	614	536	861
c) Unallocated	849	0	1,263	83	20

Total	1,958	1,382	5,281	3,711	4,831
Less: Inter Segment Revenue	0	0	0	0	0

Net Sales/Income from Operations	1,958	1,382	5,281	3,711	4,831
2. Segment Result Profits/(Loss) before tax and interest from					

a) Speciality Chemicals	(275)	4	(248)	51	65
b) Drugs & Formulations	2	(33)	(53)	(116)	7
c) Unallocated	806	0	1,220	83	12

Total	533	(29)	919	18	84
Less:					
i) Interest	34	49	98	137	175
ii) Other unallocable expenditure net of unallocable income	0	2	0	4	0

Total (Loss)/Profit before tax	499	(80)	821	(123)	(91)
3. Capital Employed - Net					

a) Chemicals	3,588	3,119	3,588	3,119	3,009
b) Bulk Drugs & Formulations	2,804	2,695	2,804	2,695	2,857
c) Unallocated common assets	435	476	435	476	614

Total	6,826	6,290	6,826	6,290	6,480

Notes:

1. The above financial statement was reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 25th January, 2006.
2. Other Income for the nine months ended December 31, 2005 includes profit on buyback of investments Rs. 317 lakhs.
3. The exceptional item includes amortisation of retirement benefits to employees under Voluntary Retirement Scheme and profit on sale of Hyderabad unit.
4. The company has concluded the business transfer agreement for slump sale of its Hyderabad unit during the current quarter. Profit on sale of the unit, disclosed as an exceptional item and tax thereon, is on an estimated basis pending final determination of net worth and profit. Difference, if any, shall be adjusted in the quarter ending March 31, 2006.
5. Current tax represents tax on Capital Gains. Deferred tax will be recognised at the end of the year after considering carry forward unabsorbed losses.
6. During the quarter total 2 (TWO) investor complaints were received, which were resolved by the company. No complaints were pending either at the beginning or at the end of the quarter.
7. The Statutory Auditors of the company have conducted the limited review of the Accounts.
8. The company has identified its main business segments as : (a) Speciality Chemicals and (b) Drugs & Formulations for a period of one month for the quarter and seven months for the nine months ended December 31, 2005 respectively.
9. Figures for the quarter and nine months ended December 31, 2005 include operations of the Hyderabad unit for one month and seven months respectively. Hence they are not comparable with the figures for the quarter and nine months ended December 31, 2004.

For and on behalf of Board of Directors

Place: Mumbai
Date: January 25, 2006

S.F.Vakil
Vice Chairperson and Managing Director

This document was created with Win2PDF available at <http://www.win2pdf.com>.
The unregistered version of Win2PDF is for evaluation or non-commercial use only.
This page will not be added after purchasing Win2PDF.